HARP News and Press, Harpoon Therapeutics Inc. From 10/04/22

Harpoon Therapeutics ( NASDAQ: HARP ) has announced the appointment of Luke Walker, M.D., as Chief Medical Officer. Dr. Walker will lead the clinical development strategy and its execution for Harpoon Therapeutics and the product candidates derived from the company&#x...

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Luke Walker, M.D., as Chief Medical Officer. Dr. Walker will lead t...

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of Lauren Silvernail to its Board of Directors and as the Chairperson...

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that management will participate in three upcoming investor conferences: Conduct one-on...

Summary Harpoon Therapeutics is an oncology platform play developing tri-specific drug candidates. The company’s lead candidates HPN217 and HPN328 are in Phase 1/2 trials and have so far shown efficacy without compromising safety. HPN217’s main takeaway is its Ab...

Harpoon Therapeutics press release ( NASDAQ: HARP ): Q2 GAAP EPS of -$0.53 beats by $0.03 . Revenue of $8.3M (+43.1% Y/Y) beats by $1.34M . For further details see: Harpoon Therapeutics GAAP EPS of -$0.53 beats by $0.03, revenue of $8.3M beats by $1.34M ...

Presented encouraging interim data for anti-DLL3 T cell engager HPN328 from ongoing dose escalation clinical trial at the 2022 ASCO Annual Meeting Portfolio prioritization and resource alignment strengthens support for the advancement of HPN328, HPN217 and HPN601 SOUTH SAN...

Harpoon Therapeutics has an intriguing platform that can generate stable bispecific immunotherapies using their TriTAC technology. Their “off-the-shelf” T-cell engagers help T-cells eliminate solid tumors and hematologic cancers. The company has several catalysts for its...

Canaccord analyst William Maughan assumed coverage of Harpoon Therapeutics ( HARP ) with a Buy rating and $16 price target. Bispecific T-cell engagers, like the ones Harpoon is developing, are "among the hottest therapeutic strategies in development for oncology," said Maughan, wh...

Appointments named for two key executive leadership positions in human resources and translational medicine SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engage...